A. Fallu

发表

A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder

L. Yatham, C. Binder, L. Yatham, 2007, Acta psychiatrica Scandinavica. Supplementum.

Adult ADHD and comorbid disorders: clinical implications of a dimensional approach

P. Chokka, M. Katzman, Larry J. Klassen, 2017, BMC Psychiatry.

Pharmacotherapy to sustain the fully remitted state.

R. Lam, S. Kennedy, R. McIntyre, 2002, Journal of psychiatry & neuroscience : JPN.

Measurable outcomes in psychiatric disorders: remission as a marker of wellness.

Roger S McIntyre, R. McIntyre, J. Konarski, 2006, Clinical therapeutics.

Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

S. Kennedy, M. O’Donovan, A. Ravindran, 2008, The Journal of clinical psychiatry.

A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic)

M. Furtado, M. Katzman, F. Dabouz, 2016, Therapeutic advances in psychopharmacology.

Does OROS*-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

C. Binder, A. Fallu, C. Richard, 2006, Current medical research and opinion.

Adult ADHD and comorbid depression: A consensus-derived diagnostic algorithm for ADHD

D. Mcintosh, C. Binder, A. Levitt, 2009, Neuropsychiatric disease and treatment.

Re: Is Adult Attention-Deficit Hyperactivity Disorder Being Overdiagnosed?

P. Chokka, M. Katzman, Larry J. Klassen, 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Re

P. Chokka, M. Katzman, Larry J. Klassen, 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.